Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt 7.2mg, Wegovy reaches its maximum licensed dose in the UK — and with that step up comes a higher likelihood of gastrointestinal side effects than at earlier stages of the titration schedule. Nausea, diarrhoea, constipation and vomiting are the most commonly reported, particularly in the weeks following a dose increase. These are prescription-only medicines; a GPhC-registered prescriber assesses whether this dose is clinically suitable before it is prescribed. Most side effects are temporary, but knowing what to watch for (and what warrants urgent medical attention) helps you manage treatment safely and confidently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The MHRA approved the dedicated 7.2mg single-dose Wegovy pen on 14 April 2026, making it the highest available maintenance dose of semaglutide for weight management in the UK. By the time most people reach it, they have already worked through four earlier dose levels over roughly sixteen weeks, so the body has had a sustained period of adjustment. That matters, because tolerance built gradually is one of the main reasons GI side effects become less disruptive over time.
Still, any dose increase carries a fresh risk of nausea and stomach discomfort as your system recalibrates. Clinical trial data for the 7.2mg dose, published alongside the MHRA's approval announcement, recorded gastrointestinal events as the most frequent adverse effects, consistent with what the NHS medicines page for semaglutide documents across the Wegovy range. The good news is that for the majority of participants, these effects were mild to moderate and transient.
The side effects that appear most often at this stage include nausea, vomiting, diarrhoea, constipation, indigestion, burping and abdominal discomfort. Fatigue, headache and dizziness are also reported, usually early in a new dose period. Injection-site reactions (redness, itching or mild swelling at the site) can occur with any subcutaneous injection and are generally minor. Our prescribers hear this question most weeks: whether the side effects at 7.2mg are meaningfully worse than those at 2.4mg, and if you want a detailed breakdown of what the earlier stages involve, our page covering the side effects people commonly report at the 1mg dose gives useful context for comparison. The honest answer is that they can be, which is why this dose requires an individual clinical decision rather than a routine step-up.
The first two to three weeks after each dose increase are typically when GI symptoms are most active. A few practical adjustments make a measurable difference for most people. Eating smaller portions, avoiding very fatty or heavily seasoned meals, and eating slowly all reduce the pressure on a stomach that is emptying more slowly than usual, gastric slowing is part of how semaglutide works, and it is also the mechanism behind much of the nausea.
Cold or room-temperature food is often better tolerated than hot meals when nausea is present. Ginger tea, plain crackers and light protein sources are frequently helpful. The titration schedule for Wegovy exists precisely because rushing to a higher dose before tolerance develops tends to amplify these effects.
Dehydration deserves separate attention. Repeated vomiting or diarrhoea can deplete fluid faster than people realise, and on a GLP-1 medicine that also reduces your thirst signals, the gap can widen quietly. Sipping water consistently through the day (rather than large amounts at once) is a practical habit worth building. If you cannot keep fluids down for more than twenty-four hours, that warrants a call to a healthcare professional, not a wait-and-see approach. You can read a broader overview of how Wegovy works if you want context on the mechanism behind these effects.
Most side effects at 7.2mg are uncomfortable rather than dangerous. Some, however, require prompt medical attention. Knowing the difference is the most important thing to take from this page.
In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis (an inflammation of the pancreas) as an infrequent but potentially serious side effect. The warning sign is severe, persistent stomach pain that may spread to the back, sometimes accompanied by vomiting. This is not the same as ordinary nausea. If you experience this pattern, stop the injection and get urgent medical help. Do not wait to see if it settles.
Other situations that need prompt medical assessment include: signs of a serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing, rapid heartbeat or severe rash); symptoms of gallbladder problems such as persistent upper-right abdominal pain or yellowing of the skin; and dehydration that progresses to dizziness, very dark urine or inability to stand without feeling faint. If you develop low mood or thoughts of self-harm, contact a healthcare professional straight away. The MHRA Yellow Card scheme allows patients to report suspected side effects directly, which helps regulators track the real-world safety profile of newer medicines like this one. Reporting matters, particularly for a medicine at a newly approved dose.
If you are unsure whether what you are experiencing is a normal adjustment reaction or something that needs attention, the nume support team is available seven days a week, and our prescribers can advise.
Side effects at 7.2mg sit in a pattern that runs through the entire Wegovy schedule. If you want to compare what people typically report at earlier stages, pages covering the 2.4mg maintenance dose and the 1.7mg step lay that out in detail. The overall picture, supported by the trial evidence reviewed by NICE in its appraisal of semaglutide for weight management (TA875), is that GI events are most frequent early in treatment and after each upward step, with the rate declining as dose and duration both stabilise.
Tolerability varies considerably between individuals. Some people move through the full titration with minimal disruption; others find specific doses harder and benefit from spending longer at an intermediate level before stepping up. That is a clinical decision, not something to manage alone. If side effects at 7.2mg are significantly affecting your quality of life, a prescriber can discuss whether staying at a lower maintenance dose is appropriate for you. The goal is sustainable treatment, not simply reaching the highest number.
For a broader look at the cost and treatment structure, the Wegovy cost page covers what is included in a private prescription. Our prescribers discuss both suitability and likely side effects as part of every consultation, check your eligibility to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.